First Author: S.Rojas Juarez MEXICO
Co Author(s): G. Rios Nequis
Back to previous
Diabetic macular edema is the leading cause of visual impairment in the USA, with 75,000 new cases per year. Its pathogenesis is multifactorial, being mainly due to the rupture of the blood - retinal barrier. A new alternative non-invasive, is the use of micropulsed laser with a wavelength of 577nm, without producing cellular damage. The aim of the study is to evaluate the therapeutic response of diabetic macular edema by combining standard therapy with intravitreal bevacizumab + macular micropulsed yellow laser 577 nm.
Fundacion Hospital Nuestra Señora de la Luz
Longitudinal and prospective study, 39 patients 55 eyes treated with micropulsed laser, diagnosed with diabetic macular edema on treatment with intravitreal bevacizumab. Patients were randomized to a single 577nm yellow micropulsed laser session on the IQ 577 Iridex Corporation California, USA. The first month and 3 months of treatment were monitored by spectral domain OCT (optical coherence tomography), and best visual acuity, with central macular thickness and macular volume variables measured by OCT. A statistical Student´s T test was performed to assess the response to treatment.
We obtained a sustained improvement of BCVA (best corrected visual acuity) of 0.11 LogMAR, with an increase in the reduction of CMT (central macular thickness) of 50 microns at the third month of treatment, with a higher macular volume reduction of 1.46 mm3. All were statistically significant except for the CMT.
In our study, the use of combined therapy with micropulsed laser and intravitreal bevacizumab in patients with diabetic macular edema is effective, being an alternative to intravitreal bevacizumab monotherapy.